Open this URL, click on the inside of the free request for bull shares you will be in the plate free of charge to get a short-term bull shares we recommend: www.dncg777.com/
000790 Huashen Group 300006 Lemay Pharmaceuticals 600267 Haizheng Pharmaceuticals 600276 Hengrui Pharmaceuticals 600200 Jiangsu Wuzhong Cancer Drugs Cancer 600594 Yibai Pharmaceuticals Vaccines Pharmaceuticals 300158 Zhendong Pharmaceuticals 300273 and good shares Electromagnetic
Anti-cancer concept stock speculation opportunities and anti-cancer concept stock summary ★ Anti-cancer concept stocks are mainly speculation or new anti-cancer drugs, cancer concept stock sea subdivided into cancer diagnostic and treatment institutions, cancer vaccines, cancer detection, cancer auxiliary treatment followed.
Linked concept: pharmaceutical plate
Active leader: Limei Pharmaceuticals, Hai Zheng Pharmaceuticals, Hengrui Pharmaceuticals, Jiangsu Wuzhong, Huashen Group, Yibai Pharmaceuticals, Zhendong Pharmaceuticals
Summary of listed companies related to the concept of anticancer stocks:
Cancer diagnosis and treatment institutions:
We are the first company in the world to be able to offer a cancer treatment institution
He is the only one to be able to do so, and we will be able to do so in the future. Tumor minimally invasive treatment field: the company is the first and currently the only one that can provide a more complete minimally invasive comprehensive treatment solutions for tumors. The company has successfully developed a series of professional equipments for minimally invasive treatment of tumors, which cover the main core areas of minimally invasive treatment of tumors, such as in vivo radiotherapy, radiofrequency ablation, interventional thermo-chemotherapy, extracorporeal hyperthermia, immune recovery therapy, and late-stage treatment of thoracic and abdominal fluid for tumors, etc. Among them, the interventional thermo-chemotherapy perfusion system and immune therapy system are both original invention products, and they have been included in the list of the first batch of recommended equipments of the State Administration of Traditional Chinese Medicine (SACT). After the successive development of the subsequent electromagnetic positioning puncture navigation system, dual-frequency electromagnetic heat therapy machine and other products, the company will realize the coverage of self-produced equipment on the main technical fields of minimally invasive tumor treatment. At present, the company's minimally invasive tumor treatment equipment covers 155 tertiary hospitals (coverage rate of 12.57%) and 172 secondary hospitals (coverage rate of 2.64%).
Huashen Group (000790) Cancer Clinics/Anti-Cancer Drugs
The company's primary liver cancer drug, iodine [131I] Metuximab Injection (Ricardin), is a National Class I Innovative Drug, the world's first gene-based drug using monoclonal antibody-targeted therapy for liver cancer, and the company has its own intellectual property rights to be used in the treatment of middle- and late-stage liver cancer. Three cancer diagnosis and treatment centers have been built in cooperation.
Dokuro (002219) Cancer Diagnostic and Treatment Facility
The company invested 120 million yuan to let the Red Cross Tumor Diagnostic and Treatment Center for 15 years 85% of the right to income. After asset evaluation of the Red Cross Tumor Diagnostic and Treatment Center 15 years 85% of the operating income right evaluation value of 142 million yuan. 2012 January to November Diagnostic and Treatment Center to achieve a net income of 31.441 million yuan. In addition, the company and the Red Cross Cancer Hospital intend to entrust the medical management of the Cancer Diagnostic and Treatment Center and the conduct of its business to Yao Yu for execution.
Cancer detection-related:
Huayu Detection (300012) carcinogen detection technology
Nitrosamine is a strong carcinogen, and can be triggered through the placenta and breast milk offspring of tumors, as well as teratogenic and mutagenic effects, the company has successfully developed 11 major concerns about the detection of nitrosamine substances; phosphate ester flame retardant has the potential carcinogenicity, teratogenicity, neurotoxicity and other toxicity, the company developed the use of gas chromatography, the company's development of a gas chromatograph to detect the carcinogen, teratogenicity, neurotoxicity and so on. Toxicity, the company developed gas chromatography - mass spectrometry technology for the detection of these five substances; organochlorine pesticides will produce a wide range of long-term harm to humans and animals, resulting in endocrine disruption of the human body, reproduction and immune system damage, and induce cancer and neurological disorders, for this reason, the company has developed the detection of 34 organochlorine pesticides specified by the AAFA, the above three technologies have reached the international advanced level. These three technologies have reached the international advanced level.
Xilong Chemical (002584) Cancer Detection Reagent
Proposed to acquire 75% of the equity of New Continental Biologicals, New Continental Biologicals with a registered capital of 20 million yuan, has developed tumor detection reagents, total antioxidant status (TAS) detection kits (FRAP method), and multiple biochemical reagents, etc., and has a certain market scale in the in vitro diagnostic reagent industry; if the acquisition is completed, the company will enter the biochemical reagent industry. If the acquisition is completed, the company will enter the biochemical reagent industry, providing a new growth point for future development.
Tiger Pharmaceuticals (300347) Clinical Medical Experimentation
Tiger Pharmaceuticals is mainly engaged in the research and development of pharmaceutical products by providing clinical research services such as technical services for phase I to IV clinical trials, data management, statistical analysis, registration and reporting, etc. As a CRO (Clinical Research Organization), the company has been engaged in the research and development of clinical trials. As a clinical trial CRO (contract research organization) enterprise, the company has a high level of clinical research, and is one of the few local CR O enterprises with the ability to conduct international multi-center trials. The company has also been in a leading position in the field of clinical research on innovative medicines, and has the experience of conducting clinical research on 35 Class I new medicines in a wide range of fields, such as hepatitis, oncology, endocrinology, cardio-cerebral and cerebral vascular and AIDS.
Rongzhilian (002642) Cancer Genome Sequence
UW Technology Partners with South Texas START to Launch San Antonio 1,000-Person Cancer Genome Project,On September 12, 2013, a subsidiary of the world's largest genomics research organization, UW Genome Technology Services Co. ("UW Tech"), a subsidiary of UW Genome, the world's largest genetics research organization, and South Texas Accelerated Research Therapeutics ("START") officially announced that the two companies will jointly develop and promote the San Antonio 1000 Cancer Genome Project ("San Antonio 1000 Cancer Genome Project"). Antonio 1000 Cancer Genome Project (SA1kCGP). The SA1kCGP is a groundbreaking project that combines genetic variation with clinical characterization, and will further facilitate the development of personalized medicine with drug-specific markers. the SA1kCGP is fully funded by private donations, and the genome-wide data of 10 common cancers obtained in the study will be made available free of charge to researchers around the globe. Rongzhilian's (002642) half-yearly report showed that it used its own funds of 15 million yuan to participate in Shenzhen Huada Gene Science and Technology Service Co.
Fosun Pharma (600196) oncology chemotherapy drug testing
The company invested $22.4 million to subscribe for 4,299,400 shares of SALADAX's Series D preferred stock, and after the completion of this subscription the company will become its single largest shareholder. At the same time, SALADAX authorized the company's subsidiary, Fosun Changzheng, exclusive distribution rights and product manufacturing rights in China.SALADAX has the world's leading testing technology and oncology chemotherapy drug monitoring product portfolio today, through this cooperation, it will effectively enhance the company's innovation in the field of medical diagnostics, and is expected to be the first to launch a biochemical testing platform in China and even in the global market, which will be able to test the concentration of oncology chemotherapy drugs and other assays. It is expected to launch a unique biochemical testing platform in China and even in the global market, which will be able to detect the concentration of tumor chemotherapeutic drugs, etc., and thus help better analyze the therapeutic effect of tumor chemotherapeutic drugs. It is expected that this product line will form a considerable sales scale in China in the future.
Daheng Technology (600288) cancer detection equipment
The company's medical equipment has the international first-class level of "whole-body tumor three-dimensional stereotactic conformal and intensity-modulated radiotherapy system (3DCRT, IMRT)", as well as a leading generation of "three-dimensional radiation therapy planning system (3DCRT, IMRT)", and "three-dimensional radiation therapy planning system (3DCRT, IMRT)", and "three-dimensional radiation therapy planning system (3DRT)". The 3DTPS and VHP are large-scale comprehensive medical devices that integrate computer technology, image processing technology, and radiation therapy equipment. Due to the undisputed technical level advantage of the product, it is now equipped in more than two hundred famous hospitals nationwide and has the first domestic market share.
Cancer vaccine-related:
Haixin (600851) intestinal cancer vaccine/anti-cancer drug
Independently researched and developed the national class I new drug, the drug is called "antigen-sensitized human dendritic cells (APDC)", which can be used for the treatment of rectal cancer, and it is produced by Haixin Bio-technology Co. The drug, called "Antigen Sensitized Human Dendritic Cells (APDC)", can be used for the treatment of rectal cancer and is developed by Haixin Biotechnology (51% owned by Haixin Biotechnology) in cooperation with the Shanghai Second Military Medical University. Haixin Bio's "Antigen Sensitized Human Dendritic Cells" (APDC) is a new generation of therapeutic tumor vaccine for colorectal cancer. (On July 26, 2012, the APDC program received approval from the State Food and Drug Administration to conduct Phase III clinical trials.)
Watson Biologicals (300142) Cervical Cancer Vaccine
Holds Shanghai Zerun (50.69% stake). Shanghai Zerun is a domestic leader in both preventive and therapeutic cervical cancer vaccine (HPV) research and development, and its recombinant HPV preventive vaccine is the first HPV vaccine in China to be developed using a eukaryotic expression system and to receive clinical trial approval.
Zhi Fei Bio (300122) Cervical Cancer Vaccine
The company signed an agreement with Merck KGaA, an affiliate of Merck KGaA, on the "Cervical Cancer Vaccine" (HPV Vaccine), agreeing to license the company to distribute it exclusively within the agreement area (Mainland China) after the agreement product is listed on the market. The Merck HPV vaccine (trade name: Jadasso) is the world's first cancer vaccine and the only cancer vaccine approved for use in the prevention of cervical cancer and precancerous lesions of the reproductive organs caused by HPV types 6, 11, 16, and 18, and is currently marketed and sold in 124 countries and regions around the world.
Cancer drugs:
GuoNong Science and Technology (000004) Anti-cancer Drugs
Huatai Pharmaceuticals, the controlling subsidiary, plans to invest a total of 213.48 million yuan in off-site expansion of its production base in Penglai. The scale of the project is an annual output of 22 million ordinary small-volume injections, 22 million ordinary lyophilized powder injections, 10 million anti-tumor lyophilized powder injections, the construction period is proposed to be 2.5 years, the production period of 1.5 years. In the long run, some of the products in the project are currently imported into the country, and now the market is better and sales are more stable.
Guojia Tongyi (000028) research and development period
The company's participation in the enterprise Wanle Pharmaceuticals (accounting for 35.19% of it) developed the anti-tumor drug doladazole.
Fengyuan Pharmaceuticals (000153) anti-cancer drugs
Fengyuan Zhongren Pharmaceuticals, a joint venture between the company and Zhongren Science & Technology (in which the company holds a 60% stake), guaranteed that the new anti-cancer drug of cisplatin implant will be listed by the end of September 2012; the company has vigorously invested in the research and development of new drugs for adjuvant cancer treatment.
Sihuan Bio (000518) Anti-cancer Drugs
The company's main products include a new class of anti-cancer drugs, including recombinant interleukin-2 for injection (used in the comprehensive treatment of renal carcinoma, malignant melanoma and other malignant tumors), recombinant interleukin-2 injection, recombinant human granulocyte-stimulating factor injection, and recombinant human erythropoietin injection, of which recombinant interleukin-2 for injection is a new class of new anti-cancer drug, which is the first class of new anti-cancer drugs. Recombinant human interleukin-2 for injection is an industrialized gene-engineered product under the national project "Development, pilot production and clinical application of genetically engineered human interleukin-2"; Beijing Sihuan Bio-Pharmaceutical, in which Beijing Sihuan Bio-Pharmaceutical still holds a 55% equity interest, is the earliest enterprise engaged in the research and production of genetically engineered pharmaceuticals and diagnostic reagents in China, and its proprietary technologies include interleukin-2 (used in the treatment of hepatocellular carcinoma), Interferon, EPO, G-CSF and other sublingual tablets.
Hainan Haiyao Pharmaceuticals (000566) anti-cancer drugs
Subsidiary Haikou City Pharmaceutical Factory bendamustine is an anti-tumor drug with dual mechanism of action of nitrogen mustard and purine analogues, there is no bendamustine listed on the market or imported, belonging to the new drugs of chemical drugs category 3.1. Paclitaxel injection produced by the company is the first listed product in China. Paclitaxel is mainly used for first-line and second-line treatment of ovarian and breast cancers and NSCLC, and also has a certain degree of efficacy for head and neck cancers, esophageal cancers, seminoma, and relapsed non-Hodgkin's lymphoma, etc. It owns the brand name and price advantage.
Changchun Gaoxin (000661) anti-cancer drugs
Changchun Jinsai Pharmaceuticals, the company's controlling subsidiary (70%), is the only national genetic engineering pharmaceutical incubation base in the pharmaceutical enterprises, its growth hormone series products have been in the country and even the Asia-Pacific region ranked first as a leader in the field of children's growth and development treatment in the field of burns, assisted reproduction, anti-aging, tumors and other areas are also being established with core competence in the field. It is also establishing a leading position with core competitive advantages in various fields such as burns, assisted reproduction, anti-aging, and oncology. Kinsey continues to maintain the No.1 market share of growth hormone in China.
Pu Luo (000739) anti-cancer drugs
The company holds 98.07% of Zhejiang Pu Luo Kang Yu Pharmaceutical production of Baxin is the national second class of new anti-tumor drugs; the company declared in the first half of 2010, "Genetic engineering enzyme synthesis of D - p-hydroxyphenylglycine Deng Potassium Salt of high-tech industrialization demonstration projects "was listed in the national high-tech industrialization demonstration project. Development and construction of pharmaceutical and R&D bases are carried out in the Pharmaceutical Industrial Park (Second Park) of Datong Development Zone, Shanxi Province. After the completion of the project, the expected capacity scale is 100 million sticks/year for aqueous injection and 20 million sticks/year for lyophilized powder injection. The total investment of the project is 25,000,000 RMB, divided into two phases. The company has completed the declaration of 4 products of cardiovascular and cerebrovascular injections, which are in the queue for review at the Drug Review Center. Meanwhile, it has completed the preliminary research of 4 special tumor injection products.
Beida Pharmaceuticals (000788) R&D period
The company cooperated with Founder Institute of Pharmaceutical Research on Compradine Disodium Phosphate (CA4P) and injections, which is a kind of vascular-targeting or endothelium-destroying drug, whose mechanism is to cause rapid interruption of tumor blood flow supply leading to tumor death due to insufficient oxygen supply and nutritional starvation, and the production approval of the drug will take about five to six years. Palonosetron hydrochloride is a second-generation 5-HT3 receptor antagonist, which is mainly used for the treatment and prevention of acute nausea and vomiting caused by moderate and severe emetogenic chemotherapy, and is mostly used as an adjuvant drug for tumors and for the prevention and treatment of nausea and vomiting after surgery. The listing of the drug will have a positive impact on the company's future performance.
Huarun Sanjiu (000999) anti-cancer drugs
Anhui Jinchan Biochemistry, in which the company holds an 83.68% stake, mainly produces the anti-cancer drug Huachansu injection, which can be used for treatment of middle- and late-stage tumors and chronic hepatitis B. The company is also a major producer of the anti-cancer drug Huachansu injection.
Huabang Yingtai (002004) anti-cancer drugs
Chongqing Huabang and Chongqing Huabang Shengkai, the company's controlling subsidiaries, have received approval from the State Drug Administration for the issuance of "Calcium Zofolic Acid Raw Material Drugs" and "Calcium Zofolic Acid for Injection" (Chemical Drug Class 3.1). (Class 3.1 of chemical drugs) approved by the State Drug Administration for issuance of drug registration approvals. Calcium levofolinate for injection is the second drug in Chongqing Huabang's oncology field, which has a positive impact on further improving the product line in the field of oncology. Clinically, levofolinic acid calcium for injection is used in combination with fluorouracil for the adjuvant treatment of gastric cancer and colorectal cancer, which can prolong the survival period. As the corresponding isomer of calcium folinate for injection, calcium levofolinate for injection has obvious advantages in efficacy and safety.
Shuanglu Pharmaceuticals (002038) anti-cancer drugs
The company has been selected as one of the "Beijing Biomedical Industry Leapfrog Development Project" and one of the first batch of "Ten Hundred Thousand Project" key cultivation enterprises in Zhongguancun National Innovation Demonstration Zone. In the fields of tumor therapy, anti-inflammatory and analgesic, cardiovascular, cerebrovascular and liver disease, the company has stockpiled a number of advantageous varieties with domestic and international market potential, and is striving to launch more than three antibody and vaccine drugs. In the field of liver disease treatment, the company will continue to cultivate heavyweight varieties, and strive to become an important enterprise in the field of liver disease treatment in China. The company's main varieties of recombinant human granulocyte colony-stimulating factor, interleukin-11, menthyl aminotransferase, anti-tumor products and other more than 10 varieties are entering the Eastern Europe, Asia, South America market one after another.
Xinlitai (002294) clinical trial period
and Tsinghua University jointly established "Tsinghua University - Xinlitai small molecule joint R & D center", to improve the cardio-cerebral vascular, anti-tumor and other major diseases, screening innovative drug capacity, enhance the efficiency of research and development; the introduction of the national class 1 innovative drug
Zongsheng Pharmaceuticals (002317) Anti-cancer Drugs
Signed a tripartite technical cooperation agreement with Guangdong South China Center for the Creation of New Drugs and Sichuan University, *** with the development of new drug projects. The three projects in the first phase of development are QU100, a new chemical class I drug for pulmonary fibrosis, WCH-016, a new chemical class I drug for type II diabetes, and DXZ923, a nanoformulation for cancer.
Essence Pharmaceuticals (002349) R&D period
R&D of the second-generation targeted anti-tumor drug betatinib: the drug has been through the synthetic route, completed the screening of salt and crystal type, prepared a small number of samples, and is carrying out the preliminary quality stability examination of the API.
Yuhang Pharmaceuticals (002437) anti-cancer drugs
Gemcitabine hydrochloride--anti-tumor drug: Gemcitabine hydrochloride for injection belongs to the anti-metabolic tumor drug, which is widely used in the treatment of pancreatic cancer and non-small-cell lung cancer, and it is only produced by three pharmaceutical factories in our country: Eli Lilly of the U.S.A., Jiangsu Hausen and Yuhang Pharmaceuticals.
Laimei Pharmaceuticals (300006) anti-cancer drugs
The company's core technologies include lymphatic targeting nanomedicine technology, drug micro-nano-dispersion and suspension preparation technology and sterile raw material preparation technology, of which the lymphatic targeting nanomedicine technology is at the international leading level; anti-tumor drugs are mainly nano-carbon suspension injection, fludarabine phosphate for injection, parenteral Anti-tumor drugs are mainly nano-carbon suspension injection, fludarabine phosphate for injection, and parenteral nutritional drugs are mainly N(2)-L-alanyl-L-glutamine injection, which have filled the gaps in China and have great clinical application value. The proportion of oncology drugs in the product structure of the company will continue to improve, the company's current proportion of anti-tumor drugs is about 20%, and is expected to exceed anti-infective drugs to reach about 40% in three years. The company's product nano carbon suspension injection is mainly used for lymphatic tracer, its introduction as a diagnostic lymphatic tracer to fill the gaps in the country, for China's first generic drug of this type of drug, the relevant product preparation technology has been protected by the national patent, the company was the first in the world to launch the product. Fludarabine phosphate for injection is suitable for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL). According to statistics, in the domestic market of fludarabine phosphate for injection, the company occupies a market share of 10.35%, and is ranked No.3 in the market.
Anke Bio (300009) anti-cancer drugs
The company intends to introduce the project of anti-tumor drug Tigio tablets, Tigio is a kind of compound anti-tumor new drug, mainly used for the treatment of advanced or metastatic gastric cancer, is expected to put into production in 2012, with an annual production capacity of 30 million tablets.
Xiangxue Pharmaceuticals (300147) R & D period
New Drugs has paid $1.5 million to KINEX Corporation*** as agreed. It is expected that it will take more than 5-6 years for KX02 to be developed into a new drug.In June 2013, KINEX was granted IND approval by the US FDA, and can initiate the Phase I clinical study of the complex (KX2-361) in the United States after submitting and amending relevant documents. At the same time, KINEX will also start the Phase I clinical study of KX02, a lipophilic anti-tumor compound that can cross the blood-brain barrier and has a clear mechanism of action, which has been proved to be effective in inhibiting malignant glioma cells in animal experiments, and has the potential to be developed into a new and effective drug for the treatment of brain tumors.
People's Health Pharmaceuticals (600079) clinical trial period
The company holds 81.07% of the shares of Hubei Gedian People's Health Pharmaceuticals is a professional engaged in the steroid hormone APIs, fertility regulating drugs and antitumor drug R & D and production enterprises; the company holds 52% of the shares of the Shenzhen Xinpeng bio-engineering is research and development of the international leading anticancer gene therapy drug project TR-1 drugs, is expected to be achieved within 3-5 years, and the company is expected to be able to develop a new drug for the treatment of brain tumor. It is expected to obtain the first class new drug certificate in 3-5 years.
Taiji Group (600129) anti-cancer drugs
Jointly developed 4 new drugs with independent intellectual property rights with scientific research institutes: new preparation of anti-cancer drugs, new drugs for diabetes (complications), and 2 new cardiovascular drugs, of which 2 have been granted with clinical approvals, and 1 is in the process of applying for production approvals, and independently screened 901, 902, 903, 904, 905 new product projects. The first new anti-tumor drug at home and abroad. The new dosage form of DXJS, the first antitumor drug at home and abroad, has completed the process research, and the preclinical research has entered the comprehensive summary stage, and is expected to complete the clinical declaration in 2013,.
Jiangsu Wuzhong (600200) clinical trial period
Holding subsidiary Wuzhong Pharmaceuticals is currently researching the "national class of new biological anti-cancer drugs recombinant human vascular endothelial inhibitor injection to obtain the research and development and industrialization of the" project is in the application for the third phase of the clinical research phase, with independent intellectual property rights, 2006, "863" was awarded the State Council of the People's Republic of China (PRC). It was supported by the national "863" program for non-small cell lung cancer.
Tailong Pharmaceuticals (600222) R&D period
The company decided to take anti-tumor and cardio-cerebral and cerebrovascular products as the new R&D direction in the next stage of development, and the dosage form of the products will be based on the small-volume injections and lyophilized powder needles.
Zhongheng Group (600252) research and development period
The company agreed to provide Peking University with not more than 100 million yuan of cooperative scientific research funds in ten years, with 10 million yuan in the first year, and then every year in accordance with the progress of the research and the funding budget, to support it to carry out single-cell sequencing research on early diagnosis of cancer, and the relevant research of the project should be combined with the therapeutic mechanism and direction of the company's related products (e.g., dinosebutyl alcohol) to facilitate the development of the company's products. The research related to the project should be combined with the therapeutic mechanism and direction of the company's related products (e.g., dihydropyrimidinol, etc.) to facilitate the promotion of the products.
Hai Zheng Pharmaceutical (600267) anti-cancer drugs
The company is China's leading manufacturer of raw materials, is one of China's largest antibiotics, antitumor drugs production base; the company's preparations under construction in the export base of the project annual production capacity of cytotoxic antitumor drugs in aqueous injections of 25 million vials, lyophilized powder 25 million vials, solid preparations of 160 million tablets; the company's gene drug tumor necrosis factor receptor antibody fusion protein is currently in the process of development. The company's gene drug tumor necrosis factor receptor antibody fusion protein has entered the phase II clinical trials.
Hengrui Medicine (600276) anti-cancer drugs
The company's single-enantiomer chiral drug - calcium levofolinate can be used to enhance the anti-tumor activity of 5-fluorouracil, mainly for the treatment of osteosarcoma after high-dose methotrexate treatment and folate antagonism related to the symptoms and colon cancer, renal cancer; the company's a variety of anti-tumor drugs ranked first in the country, of which three products are exclusive production in China. Three of these products are exclusive production in China, the existing generic drugs oxaliplatin and docetaxel are in the growth period, and irinotecan is also entering the rapid growth period; the company is to have molecularly targeted antitumor drugs apatinib mesylate.
Meiro Pharmaceuticals (600297) anti-cancer drugs
Anti-tumor drug Amifotine: Anti-tumor drug Amifotine is the company's main product, the standard name of the drug injectable aminophosphoric acid, belongs to the category of western medicine injection. It can selectively protect normal organs from the toxic attack of chemotherapy and radiotherapy, and is applicable to various tumor patients in the process of radiotherapy and chemotherapy for patients with malignant blood diseases. The company undertook the "improve the quality of aminophosine and preparations and technical standards research" in the National Twelfth Five-Year Plan for the creation of major new drugs project.
Yabao Pharmaceuticals (600351) anti-cancer drugs
Anti-tumor drugs such as injectable vinblastine sulfate and other lyophilized powder needle preparations.
Kang Enbei (600572) clinical trial period
The company's wholly-owned subsidiary, Hong Kong Kang Enbei Company's participation in the research and development of Far East Super Laboratory "recombinant high-efficiency composite interferon" has obtained the first phase of the clinical trial in Singapore, the drug is the use of protein spatial regulation technology, the successful development of a protein with a new spatial conformation of a non-natural, non-natural interferon. This drug is a new type of non-natural interferon with a new spatial conformation, which can be used to inhibit viral replication and anti-tumor therapy. Far East Laboratories was incorporated in the British Virgin Islands on October 28, 2005, and is mainly engaged in the research and development of cancer treatment drugs based on recombinant high-efficiency complex interferon (RSIFN-CO) products and technology.
Yibai Pharmaceuticals (600594) anti-cancer drugs
The company has gene technology of anti-tumor Chinese medicine Aidi injection products, in addition to the purchase of the VEGI proprietary technology that can be used to obtain polypeptide chain products using genetic engineering methods, which can be used to directly activate the different types of immune cells in order to inhibit or eliminate cancer cells. The research of Aidi injection has reached the genetic level (Aidi injection is an anti-tumor traditional Chinese medicine, which is the company's exclusive product) The company's first-line product, Aidi, is an exclusive variety of anti-tumor traditional Chinese medicine injections, which accounts for about 45% of the revenue. Aidi in tertiary hospital sales accounted for about 80% of the sales of the variety, Lopatin for the latest listing of the third generation of platinum anti-tumor drugs, is the only exclusive variety of the domestic 5 platinum anti-tumor drugs, is currently in a period of rapid growth.
Magic Pharmaceuticals (600613) anti-cancer drugs
The company's subsidiary, Guizhou Jinqiao Pharmaceuticals, small-volume injections (anti-tumor drugs) has passed the new version of the national GMP certification, which has been published yesterday. It is reported that this time through the GMP certification for the zebrano sodium injection of anti-cancer drugs. The company holds a 92.58% stake in Jinqiao Pharmaceuticals, Sodium Zanthate Injection is suitable for the treatment of primary liver cancer and other tumors. 2013 interim report shows that Sodium Zanthate Injection and related products constitute nearly 20% of the company's main revenue.
Ha Pharmaceutical Company (600664)
The bioengineering company is mainly dedicated to the production and sale of drugs for tumors, cardiovascular and cerebral vascular diseases and liver diseases. Currently, the company's products include recombinant human interferon ɑ-2B for injection (trade name: Lifanen), recombinant human erythropoietin injection (trade name: Cedarson), recombinant human granulocyte-stimulating factor injection (trade name: Riajin) and other bio-engineered products, as well as new chemical preparations such as fatty milk of Prostadil, among which recombinant human interferon ɑ-2B for injection and Prostadil injection have the leading market share in the country. leading position in China.
Non-pharmaceutical main business involved in the concept of anti-cancer related listed companies:
Zhongzhu Holdings (600568) R & D period
Holding subsidiary Qianjiang Pharmaceuticals and the U.S. company TNI cooperation in the research and development of blood, bone marrow hematopoietic system cancers and cancer patients immune recovery of preclinical research on anticancer drugs, the Qianjiang Pharmaceuticals preclinical trial costs are expected to be 10 million yuan. If not passed to obtain clinical approval will be refunded 80% of the preclinical trial costs paid.
Sharp Peak Group (600668) anti-cancer drugs
Sharp Peak Pharmaceuticals, a subsidiary of the holding company, the completion of the project to form an annual output of 35 tons of cephalosporins, antineoplastic drugs, such as raw materials production line (for the preparation of supporting) and 200 million of various types of powder injection production line. 2012 April 10 announcement, the company 99.16% of the holding of the sharp Peak Pharmaceuticals intends to invest 39 million yuan (according to the stage of results) and China Pharmaceutical Science and Technology Corporation. (payable in installments) to cooperate with China Pharmaceutical University and its Institute of Pharmaceutical and Chemical Research and other related parties to carry out preclinical research on a new class of anti-tumor drugs (DPT).
Dongyang Sunshine Aluminum (600673) R&D period
Dongyang Sunshine Aluminum participates in the research and development of anti-hepatitis B and oncology new drugs. Dongyang Sunshine Innovative Drugs Scientific Research Team introduced by Guangdong Dongyang Sunshine Pharmaceutical Co., Ltd. takes anti-tumor and anti-virus chemical 1.1 new drugs as the main research and development direction, and devotes itself to the research and development of 1.1 chemical new drugs with international advanced level. At present, there is no such drug on the market in the world, and if the project is successfully developed, it will also fill the gaps in the field of new tumor drugs in China.
Lansen (600826) anti-cancer drugs
The company's participation in 34.65% of Lansen Guojian Pharmaceuticals and CITIC Pacific *** with the investment in the establishment of "Shanghai CITIC Guojian Pharmaceuticals Company Limited", Lansen Guojian accounted for 41.69% of the company's share of 0.73%. 08 CITIC Guojian development of biological new drug "Isep". In 2008, CITIC Guojian's new biopharmaceutical "Isep" (recombinant human 11 tumor necrosis factor receptor-antibody fusion protein for injection) won the Second Prize of the National Science and Technology Invention Award, and it is the first humanized monoclonal antibody drug in China that has been truly industrialized and marketed in the market. We have completed the construction of four 750-liter cell culture production lines and successfully put them into production, with an annual production capacity of 4 million units of milligram loading.
Yatai Group (600881) anti-cancer drugs
The company takes biological vaccines and anti-tumor series of drugs as the direction of new product development, and has already formed a series of anti-cancer products led by "Senyi capsule" and anti-cancer biological missile, and also reserves interleukin-11, ginsenoside RG3 injection, and other new anti-cancer drugs under research.
Auxiliary treatment of cancer:
Zhendong Pharmaceutical (300158) auxiliary treatment of cancer
The core leading product, Yanshu injection, is an auxiliary treatment of cancer, which has the effect of inhibiting cancer pain and bleeding, inhibiting tumor growth, and increasing the effectiveness and reducing the toxicity of combined radiotherapy.
Ealing Pharmaceuticals (002603), a wholly-owned subsidiary of the company, has established a pharmaceutical research center in collaboration with Cardiff University in the UK. The center will carry out in-depth exchanges and cooperation around the target research, clinical application, and market resource *** enjoyment of Chinese medicine anti-tumor. It is found that Yangzheng Xiejiu Capsule can inhibit tumor neoangiogenesis, thus inhibiting tumor growth and metastasis. Nourishing and eliminating accumulation capsule is mainly used for the adjuvant treatment of tumors, and combined with chemotherapeutic drugs to help improve the efficacy of chemotherapy. Nourishing Zheng eliminating accumulation capsule with interventional therapy for primary liver cancer has remarkable efficacy in increasing the effect and reducing the toxicity, enhancing the immunity, improving the symptoms and improving the quality of life.
Haisike (002653) Cancer adjuvant therapy
Liaoning Haisike, a subsidiary of the company, has been granted with the approval of drug registration for the national Class 6 chemical drugs "Methylprednisolone Succinate" and "Injectable Methylprednisolone Sodium Succinate". Methylprednisolone is one of the most widely used adrenocorticotropic hormone drugs, which can be clinically applied to the treatment of patients with severe diseases in many departments, such as allergic diseases, malignant tumors, etc. Methylprednisolone (injection) has been approved for drug registration. Methylprednisolone (injection) is a Class B drug in the National Health Insurance Catalog, and the listing of this drug will enrich the company's product line and have a positive impact on the company's future performance.
Golden Flower (600080) cancer auxiliary treatment
Transfer factor oral solution is used to treat viral infections and autoimmune diseases. It is also used in the adjuvant treatment of malignant tumors and tumor patients after radiotherapy.
Pientzehuang (600436) Traditional Chinese Medicine Anti-cancer/Cancer Auxiliary Drug
The main ingredients of Pientzehuang include oxalis, musk, panax ginseng and snake gall valuable herbs. In addition to treating acute and chronic viral hepatitis caused by heat and blood stasis, carbuncle and furuncle, anonymous swelling and poison, bruise and all kinds of inflammation, Pientzehuang can also inhibit the growth of digestive system cancer cells, and can be used as a kind of antitumor adjuvant medicine, for which the company applies for the patent of research and development and is accepted.
Kangyuan Pharmaceuticals (600557) Chinese medicine anti-cancer/cancer adjuvant
The pain injection it produces is a pure Chinese medicine injection used to treat moderate and severe cancer pain, with independent intellectual property rights, the company plans to make it at least partially substitute for opioid painkillers within a few years through effective promotion, becoming the first-line varieties of cancer pain treatment drugs in China.
Anti-tumor drug intermediates:
Fuan Pharmaceuticals (300194) Anti-tumor drug intermediates-amitrazine raw materials
Kincheng Pharmaceuticals (300233) Anti-tumor drug intermediates-phenyl isocyanate
Yaben Chemical (300261) Anti-tumor drug intermediates-small molecules of targeted anti-tumor drugs and their intermediates stock theory